GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Intrinsic Value: Projected FCF

Mankind Pharma (BOM:543904) Intrinsic Value: Projected FCF : ₹0.00 (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-26), Mankind Pharma's Intrinsic Value: Projected FCF is ₹0.00. The stock price of Mankind Pharma is ₹2063.45. Therefore, Mankind Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Mankind Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:

BOM:543904's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.57
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Mankind Pharma Intrinsic Value: Projected FCF Historical Data

The historical data trend for Mankind Pharma's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Intrinsic Value: Projected FCF Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Intrinsic Value: Projected FCF
- - - - -

Mankind Pharma Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mankind Pharma's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Price-to-Projected-FCF falls into.



Mankind Pharma Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Mankind Pharma  (BOM:543904) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Mankind Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2063.45/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mankind Pharma Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mankind Pharma (BOM:543904) Business Description

Traded in Other Exchanges
Address
262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines